Emergent nabs US government contract of up to $235.8M for anthrax vaccine news2024-01-11T15:41:32+00:00January 11th, 2024|Endpoints News|
#JPM24: Greg Verdine’s LifeMine eyes the clinic next year with T-cell immunosuppressive and antifungalnews2024-01-11T15:12:30+00:00January 11th, 2024|Endpoints News|
Dermavant’s PhIII eczema data; Oxford’s Nipah vaccine; Inventiva’s €25M lifelinenews2024-01-11T14:45:31+00:00January 11th, 2024|Endpoints News|
BioNTech pays $20M upfront for two monoclonal antibodies from China’s WuXi Biologicsnews2024-01-11T12:08:51+00:00January 11th, 2024|Endpoints News|
FDA approves import of French antibiotics to combat syphilis drug shortage news2024-01-11T11:10:49+00:00January 11th, 2024|Endpoints News|
#JPM24: Madrigal says it’s ‘well on the way’ to potential NASH launch ahead of FDA decisionnews2024-01-11T09:38:32+00:00January 11th, 2024|Endpoints News|
#JPM24: Cigna CEO says the insurance giant is paying attention to healthcare services to buynews2024-01-11T09:34:59+00:00January 11th, 2024|Endpoints News|
#JPM24 quick hits: Ionis on partnership’s pros and cons; Novo Ventures has $600M to spend; Are small molecules back? + morenews2024-01-10T23:06:29+00:00January 10th, 2024|Endpoints News|
#JPM24: Sanofi says it may look at next generation of weight loss drugsnews2024-01-10T22:43:43+00:00January 10th, 2024|Endpoints News|
How generic drug sponsors can ask FDA to reconsider applications: new draft guidance explainsnews2024-01-10T22:29:56+00:00January 10th, 2024|Endpoints News|
